Skip to content

Slower progression of digital acoustic speech measures in early Parkinson’s Disease under prasinezumab during the first 52 weeks of the PASADENA study

316 early-stage, drug-naive PD participants of the PASADENA Phase II study were remotely monitored with the Roche PD Mobile Application v2, including a speech test. 18 acoustic features of hypokinetic dysarthria were considered. In an exploratory analysis, treatment effect was assessed using LME models, censored for any symptomatic treatment, at significance level of α=5%, uncorrected. All features evidenced good-to-excellent ICCs, 5/18 features showed reduced progression slopes in the prasinezumab arm.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically